GET DAILY SIGNALSWhy Is Moderna (MRNA) Stock Down -6.97% Today?
Key Takeaways
- Moderna (MRNA) shares fell 6.97%, or $17.34, to close at $231.35, down from a prior close of $248.69.
- The primary catalyst was the company's 2026 Analyst Day, where management guided to roughly $4 billion of cash costs in 2027 and $4 billion to $4.5 billion annually through 2030, driven by oncology investment.
- Formal 2027 financial guidance was deferred to the fourth-quarter earnings call, leaving investors without the near-term detail they wanted.
- Secondary drivers: profit-taking after a 52-week high of $280.80 on November 9, and wide weakness across biotechnology, where 74 of 79 large peers closed lower.
- The S&P 500 slipped 0.3%, the Nasdaq about 0.35% and the health care sector roughly 0.6%, so the drop was mostly company-specific.
- Volume was light at about 3.5 million shares versus a 20-session average near 8.7 million, consistent with orderly profit-taking rather than a rush for the exits.
- News Significance Score: 24/100 - Moderate spending-and-guidance news produced a pullback well within this stock's normal daily range.
- Investors can explore detailed Price Targets, Earnings history and forward-looking Forecast pages for deeper context on the name.
- For AI-driven ideas across thousands of tickers, explore Trending AI Robots.
Opening Summary
Moderna, Inc. (MRNA) is the Cambridge, Massachusetts-based mRNA medicines company whose portfolio spans COVID-19 and flu vaccines, RSV shots and an experimental personalized cancer therapy. On November 12, 2026, the stock fell 6.97% to $231.35 from the prior close of $248.69, a decline of $17.34, after trading in a range of $229.69 to $245.37. The direction was clearly negative. Markets attributed the drop to the company's Analyst Day, where a heavier medium-term spending framework and the absence of formal 2027 guidance overshadowed an otherwise constructive pipeline update, with broad biotech weakness adding pressure.
Analyst Day Reframes the Cost Trajectory
The centerpiece of the session was Moderna's outlook for cash costs. Management said it expects approximately $4 billion in cash costs in 2027 and annual cash costs of roughly $4 billion to $4.5 billion from 2027 through 2030, primarily reflecting increased investment in oncology. That marks a change in narrative: a year earlier the company had framed 2027 cash costs at $3.5 billion to $3.9 billion on a path toward cash breakeven in 2028. Moderna has accelerated cost reductions into 2026, guiding to about $2.7 billion of R&D and 15% to 25% revenue growth with roughly 10 percentage points of gross margin expansion, but the 2027 framework implies spending stops falling and then climbs.
The optics matter for a stock priced at roughly 37 times trailing sales. Consensus 2028 revenue near $3.7 billion sits below the $4 billion-plus annual cash-cost run rate, which forces investors to underwrite either faster commercialization or further external funding. Management said it expects to end 2026 with about $9 billion of total liquidity, including cash, investments and undrawn borrowing capacity, and amended its $1.5 billion credit facility with Ares Management Credit Funds, extending maturity to 2031 and cutting the drawn rate by 75 basis points. Formal 2027 guidance was pushed to the fourth-quarter call.
Pipeline News Was Positive but Already Discounted
Moderna used the event to detail its oncology push. Intismeran autogene (mRNA-4157/V940), developed with Merck (MRK), cut the risk of recurrence or death by 42% and distant metastasis or death by 38% versus Keytruda alone in resected high-risk melanoma. The company is preparing a U.S. filing by year-end, targeting a 2027 launch, with its Marlborough facility set to become the global supply site. The data were published in a major medical journal on November 11, one day earlier, and were already reflected in a share price that had risen roughly 650% year to date.
Profit-Taking After a Historic Run
Context explains much of the magnitude. Moderna closed at a 52-week high of $269 on November 9, having touched $280.80 intraday, and had returned more than 770% over twelve months versus about 12% for the S&P 500. With the analyst day adding no new near-term number and consensus still a "Hold" with an average target materially below the market price, holders had a clear reason to lock in gains. The stock remains far above its 50-day and 200-day moving averages near $200 and $95, so the pullback left the longer uptrend intact.
Market Context and Trading Activity
The move was not a market event. The S&P 500 fell 0.3%, the Nasdaq about 0.35% and the health care sector fund roughly 0.6%. Biotechnology was the weak spot: 74 of 79 other companies with a market value above $2 billion closed lower, with a median decline of 3.0%, and 21 fell 5% or more. Moderna's drop was more than double the median peer, so sector drift amplified rather than caused the decline. Volume of about 3.5 million shares ran well below the 20-session average of roughly 8.7 million, the lightest reading in roughly two months. Notable positives in the same session, including MSCI World Index inclusion announced that morning, were not enough to offset selling.
News Significance Score
The scale runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. This event lands at 24 out of 100.
The verified news was moderate: a decision to reinvest into oncology and a medium-term cash-cost framework above the prior path, coupled with a deferral of 2027 guidance. It is material for a richly valued company but is not a clinical or regulatory verdict. The price move was unremarkable by the stock's own standards, at roughly 0.9 times its typical daily move over the past 60 sessions, with 13 sessions in that window posting equal or larger swings. Moderate news plus an ordinary move produces a low combined score.
What Comes Next for MRNA
Attention turns to the fourth-quarter and full-year 2026 report expected in February 2027, when formal 2027 guidance should quantify how much of the oncology spending is offset by revenue. Management also participates in an investor conference on November 18. Investors will watch whether the 2026 revenue range of 15% to 25% growth lands at the top end, given that the implied figure sits slightly below consensus. On the pipeline side, the timing of the intismeran U.S. submission and any additional readouts, including a kidney cancer analysis, are the key binary events. Risks include the lumpiness of international COVID vaccine sales, the company's continued unprofitability, rising cash costs from 2027, and a valuation that leaves little room for execution missteps, alongside the possibility that a stronger 2027 revenue outlook later eases spending concerns.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under present market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the featured selection changes as conditions shift. Reviewing the current lineup is a practical way to see which approaches are working now, and readers are invited to explore the page and compare the active bots against their own watchlists.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for MRNA turns positive, indicating new upward trend
MRNA saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 76 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 100 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 25 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 56 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.498). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement